Merck continues to expand oncology pipeline with $773m deal 11-Jun-2019 By Vassia Barba & Ben Hargreaves Merck acquires Tilos, a biopharmaceutical developer targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.